ZA200600229B - Pyrrole-2,5-dithione derivatives as Liver X receptor modulators - Google Patents
Pyrrole-2,5-dithione derivatives as Liver X receptor modulatorsInfo
- Publication number
- ZA200600229B ZA200600229B ZA200600229A ZA200600229A ZA200600229B ZA 200600229 B ZA200600229 B ZA 200600229B ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 A ZA200600229 A ZA 200600229A ZA 200600229 B ZA200600229 B ZA 200600229B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrole
- liver
- receptor modulators
- dithione
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316237.7A GB0316237D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200600229B true ZA200600229B (en) | 2007-04-25 |
Family
ID=27741986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200600229A ZA200600229B (en) | 2003-07-11 | 2006-01-10 | Pyrrole-2,5-dithione derivatives as Liver X receptor modulators |
Country Status (26)
Country | Link |
---|---|
US (1) | US20060189663A1 (de) |
EP (1) | EP1646625B1 (de) |
JP (1) | JP2007521313A (de) |
KR (1) | KR20060034284A (de) |
CN (1) | CN100478340C (de) |
AR (1) | AR045720A1 (de) |
AT (1) | ATE399776T1 (de) |
AU (1) | AU2004256000B2 (de) |
BR (1) | BRPI0412479A (de) |
CA (1) | CA2532068A1 (de) |
CO (1) | CO5640134A2 (de) |
DE (1) | DE602004014772D1 (de) |
ES (1) | ES2308205T3 (de) |
GB (1) | GB0316237D0 (de) |
HK (1) | HK1088318A1 (de) |
IL (1) | IL172759A0 (de) |
IS (1) | IS8291A (de) |
MX (1) | MXPA06000447A (de) |
NO (1) | NO20060080L (de) |
RU (1) | RU2006102129A (de) |
SA (1) | SA04250203B1 (de) |
TW (1) | TW200507836A (de) |
UA (1) | UA82108C2 (de) |
UY (1) | UY28407A1 (de) |
WO (1) | WO2005005416A1 (de) |
ZA (1) | ZA200600229B (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2592771A1 (en) | 2005-01-10 | 2006-07-13 | Astrazeneca Ab | Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators |
SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
SE0500058D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 5 |
JP4936476B2 (ja) * | 2005-06-28 | 2012-05-23 | 第一三共株式会社 | Lxrリガンドの試験方法 |
JP5349306B2 (ja) | 2006-08-21 | 2013-11-20 | ジェネンテック, インコーポレイテッド | アザベンゾチオフェニル化合物および使用方法 |
US10004703B2 (en) | 2006-10-12 | 2018-06-26 | Biogen Chesapeake Llc | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels |
WO2008046014A1 (en) * | 2006-10-12 | 2008-04-17 | Remedy Pharmaceuticals, Inc. | Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors |
US20100143270A1 (en) * | 2007-02-21 | 2010-06-10 | University Of Louisville Research Foubdation | Therapeutic cotinine compositions |
DK2868315T3 (en) | 2007-12-04 | 2017-09-04 | Biogen Chesapeake Llc | IMPROVED FORMULATIONS AND PROCEDURES FOR FREEZING DRYING AND THEREOF, LYOFILATES PREPARED |
WO2009097443A2 (en) | 2008-01-29 | 2009-08-06 | Remedy Pharmaceuticals, Inc. | Liquid formulations of compounds active at sulfonylurea receptors |
WO2010003025A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
CN102137843A (zh) | 2008-07-01 | 2011-07-27 | 健泰科生物技术公司 | 作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法 |
BR112013005425A2 (pt) | 2010-09-07 | 2018-05-02 | Snu R&Db Foundation | compostos sesterterpenos e suas utilizações |
EP3091970B1 (de) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr-agonisten und verwendungen davon |
CA3010883A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Methods for the treatment of myeloid derived suppressor cells related disorders |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
KR200492570Y1 (ko) | 2018-12-04 | 2020-11-05 | 박규환 | 조립식 계단장치를 위한 발판 |
JP2023509845A (ja) | 2019-12-13 | 2023-03-10 | インスピルナ,インコーポレーテッド | 金属塩及びその使用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2234300T3 (es) * | 1998-10-08 | 2005-06-16 | Smithkline Beecham Plc | 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa. |
EP1212065A4 (de) * | 1999-07-08 | 2004-02-11 | Tularik Inc | Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels |
-
2003
- 2003-07-11 GB GBGB0316237.7A patent/GB0316237D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119119A patent/TW200507836A/zh unknown
- 2004-07-05 SA SA4250203A patent/SA04250203B1/ar unknown
- 2004-07-08 KR KR1020067000616A patent/KR20060034284A/ko not_active Application Discontinuation
- 2004-07-08 EP EP04749151A patent/EP1646625B1/de active Active
- 2004-07-08 ES ES04749151T patent/ES2308205T3/es active Active
- 2004-07-08 RU RU2006102129/04A patent/RU2006102129A/ru not_active Application Discontinuation
- 2004-07-08 AT AT04749151T patent/ATE399776T1/de not_active IP Right Cessation
- 2004-07-08 AU AU2004256000A patent/AU2004256000B2/en not_active Ceased
- 2004-07-08 JP JP2006520139A patent/JP2007521313A/ja not_active Withdrawn
- 2004-07-08 US US10/563,676 patent/US20060189663A1/en not_active Abandoned
- 2004-07-08 DE DE602004014772T patent/DE602004014772D1/de not_active Expired - Fee Related
- 2004-07-08 CA CA002532068A patent/CA2532068A1/en not_active Abandoned
- 2004-07-08 AR ARP040102418A patent/AR045720A1/es not_active Application Discontinuation
- 2004-07-08 WO PCT/SE2004/001115 patent/WO2005005416A1/en active IP Right Grant
- 2004-07-08 CN CNB2004800197194A patent/CN100478340C/zh not_active Expired - Fee Related
- 2004-07-08 MX MXPA06000447A patent/MXPA06000447A/es not_active Application Discontinuation
- 2004-07-08 BR BRPI0412479-0A patent/BRPI0412479A/pt not_active IP Right Cessation
- 2004-07-09 UY UY28407A patent/UY28407A1/es unknown
- 2004-08-07 UA UAA200600270A patent/UA82108C2/uk unknown
-
2005
- 2005-12-22 IL IL172759A patent/IL172759A0/en unknown
-
2006
- 2006-01-05 NO NO20060080A patent/NO20060080L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600229A patent/ZA200600229B/xx unknown
- 2006-01-20 CO CO06005238A patent/CO5640134A2/es not_active Application Discontinuation
- 2006-02-09 IS IS8291A patent/IS8291A/is unknown
- 2006-08-07 HK HK06108722.2A patent/HK1088318A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2004256000B2 (en) | 2007-07-26 |
SA04250203B1 (ar) | 2008-02-25 |
AR045720A1 (es) | 2005-11-09 |
BRPI0412479A (pt) | 2006-09-19 |
EP1646625B1 (de) | 2008-07-02 |
ES2308205T3 (es) | 2008-12-01 |
US20060189663A1 (en) | 2006-08-24 |
CO5640134A2 (es) | 2006-05-31 |
CA2532068A1 (en) | 2005-01-20 |
KR20060034284A (ko) | 2006-04-21 |
HK1088318A1 (en) | 2006-11-03 |
CN100478340C (zh) | 2009-04-15 |
WO2005005416A1 (en) | 2005-01-20 |
IL172759A0 (en) | 2006-04-10 |
GB0316237D0 (en) | 2003-08-13 |
MXPA06000447A (es) | 2006-04-07 |
IS8291A (is) | 2006-02-09 |
UA82108C2 (uk) | 2008-03-11 |
JP2007521313A (ja) | 2007-08-02 |
AU2004256000A1 (en) | 2005-01-20 |
TW200507836A (en) | 2005-03-01 |
UY28407A1 (es) | 2005-02-28 |
DE602004014772D1 (de) | 2008-08-14 |
NO20060080L (no) | 2006-02-08 |
RU2006102129A (ru) | 2006-08-27 |
EP1646625A1 (de) | 2006-04-19 |
ATE399776T1 (de) | 2008-07-15 |
CN1820003A (zh) | 2006-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL172759A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
IL172760A0 (en) | Pyrrole-2,5-dithione derivatives as liver x receptor modulators | |
IL177218A0 (en) | 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators | |
IL178767A0 (en) | Indolyl derivatives as liver - x - receptor modulators | |
HK1092143A1 (en) | Thiazole derivatives as cannabinoid receptor modulators | |
ZA200606974B (en) | Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives | |
HK1088003A1 (en) | 3-substituted 5,6-diaryl-pyrazine-2-carboxamide and-2-sulfonamide derivatives as cb1 modulators | |
EP1684762A4 (de) | Harnstoff-derivate als kinase-modulatoren | |
EP1790650A4 (de) | Neue substituierte imidazolderivate | |
ZA200604645B (en) | Azabicyclic heterocycles as cannabinoid receptor modulators | |
GB0400440D0 (en) | Receptor modulators | |
AU2003259482A1 (en) | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators | |
ZA200609234B (en) | Substituted azeplne derivatives as serotonin receptor modulators | |
IL183140A0 (en) | Substituted benzoquinolizine derivatives | |
ZA200506744B (en) | PyrazoloÄ1,5-AÜpyrimidine derivatives | |
EP1670483A4 (de) | 17-heterocyclische 4-azasteroid-derivate als androgen-rezeptormodulatoren | |
SG121943A1 (en) | Compositions for multi-color, light activated imaging | |
HK1101856A1 (en) | Pyrrolidine-3,4-dicarboxamide derivatives | |
IL182739A0 (en) | Acylatednonadepsipeptides used as lysobactin derivatives | |
PL1638940T3 (pl) | Pochodne pirolidyniowe jako ligandy dla receptora muskarynowego M3 | |
AU2003301299A1 (en) | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators | |
AP2501A (en) | Substituted pyrrole derivatives | |
IL173337A0 (en) | Receptor | |
EP1641464A4 (de) | 17-acetamido-4-azasteroid-derivate als androgen-rezeptor-modulatoren | |
EP1641761A4 (de) | 17-acetamido-4-azasteroidderivate als androgenrezeptormodulatoren |